DCGI recommends Serum Institute’s qHPV vaccine against cervical cancer

New Delhi: The Drugs Controller General of India’s (DCGI) Subject Expert Committee on Wednesday recommended Serum Institute‘s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.

“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India‘s indigenously-developed India’s first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer,” a source said.

The vaccine has been recommended for cervical cancer patients – those above 9 years to 26 years of age – for both male and female.

According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI) and it may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.

Cervical cancer forms 16.5 per cent of the total cancer cases in Indian women and is the second most common type of cancer amongst women in the country after breast cancer. It is caused by the human papillomavirus (HPV), a virus that is generally transmitted through sexual contact.

  • Related Posts

    • Pharma
    • June 11, 2025
    • 17 views
    The idea of Modern Medtech Park in Delhi germinates

    Delhi’s Industry Minister sounded amenable, signals west Delhi as site New Delhi: Modern Medical Device Manufacturing Cluster in Delhi may become a reality in foreseeable future. The Surgical Manufacturers &…

    • Pharma
    • June 11, 2025
    • 49 views
    Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

    Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure Cadila Pharmaceuticals Limited, one of India’s most respected and innovation-driven pharmaceutical companies, has announced the launch…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    The idea of Modern Medtech Park in Delhi germinates

    The idea of Modern Medtech Park in Delhi germinates

    Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

    Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

    AMTZ moves to build ‘Device’ to rate Buildings on Accessibility Quotient

    AMTZ moves to build ‘Device’ to rate Buildings on Accessibility Quotient

    Eye stroke alert: Ozempic linked to rare vision-loss condition

    Eye stroke alert: Ozempic linked to rare vision-loss condition